ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibiting ABL1 with tyrosine kinase inhibitors (TKIs), which is used for chronic myelogenous leukemia (CML), reduced the proviral load (PVL) in vitro.